The development of resistance mutations and human immunodeficiency virus (HIV) RNA levels were compared in lymph nodes and plasma of patients receiving antiretroviral therapy. Ten HIVpositive patients receiving high-dose saquinavir monotherapy (3600 or 7200 mg/day) underwent 14 lymph node biopsies before and during therapy. HIV RNA levels and appearance of resistance mutations to saquinavir were determined in simultaneous lymph node and plasma samples. HIV RNA levels were found to be consistently higher (mean, 3.16 log RNA copies; SD, 1.04; range, 2.23 -5.59) in lymph nodes than in simultaneous plasma samples. Saquinavir therapy resulted in a reduction in HIV RNA levels in both plasma and lymph nodes. The presence or absence of a resistance mutation to saquinavir at codons 48 or 90 of the HIV-1 protease gene was identical in 13 of 14 biopsies, suggesting that resistance mutations to saquinavir appear within close temporal proximity in lymph nodes and plasma.
Recent studies with combination antiretroviral therapy
Methods have shown suppression of plasma human immunodeficiency Study population. Patients were enrolled in the Stanford saquivirus (HIV) RNA levels to õ500 copies in many patients navir high-dose study, in which HIV-positive volunteers with CD4 [1, 2] . This suppression of replication is believed to reduce cell counts of 200-500 were treated with saquinavir monotherapy, the virus's potential for generating drug-resistant mutant 3600 or 7200 mg/day, in six divided daily doses for a minimum strains and thus is hoped to lead to prolonged and possibly of 24 weeks [8] . Patients showing continuing response were alchronic suppression of viral replication and disease manifeslowed to continue to receive therapy.
tation [3] .
Lymph node biopsies. Fourteen biopsies were done on 10 pa-
The concern that viral replication may be continuing at levels tients. Biopsies were done at three time points: 2 at baseline before below 500 copies has led to the development of ultrasensitive starting therapy, 7 early in the course of therapy (weeks 4-12), when plasma virus load levels which had initially dropped first plasma assays capable of detecting as low as 20 copies [4] . A began rising, and 5 late in the course of therapy (weeks 24-56), number of studies have shown lymph node HIV RNA levels when plasma virus load levels were returning to baseline values.
to be greater than those found in plasma [5 -7] . This would Patients had biopsies performed at one or two of these time points.
suggest that even in patients with plasma HIV RNA levels of Both early (weeks 4-12) and late weeks (weeks 24-56) were õ20 copies, continued HIV replication may be present in the chosen for sampling, since plasma virus from patients at the time lymphoid tissue, allowing for the eventual development of drug of first failure often lacks detectable drug resistance mutations, resistance mutations and ultimately to drug failure and loss of whereas sampling later on after weeks or months of failure often virus suppression. The degree to which higher virus loads may reveals drug-resistant virus [8] .
effect the development of resistance mutations in the lymph then disrupted by gently pressing the tissue through a 100-mesh tissue sieve (Cellector; Bellco Glass, Vineland, NJ). The sieve was rinsed with 1 mL of PBS (pH 7.2), and the resulting cell suspension was collected and centrifuged for 5 min at 400 g. The acellular supernatant was collected, aliquoted, and stored at 070ЊC. The 
Results
Two patients had lymph nodes biopsied before and after 4 weeks of therapy (figure 2). Both showed a reduction in HIV Lymph node mutations. Mutations in the protease gene at RNA load in their plasma accompanied by a corresponding codons 48 and 90, which have been associated with resistance reduction in their lymph nodes. In the patient shown at the left to saquinavir, were determined in the plasma virion RNA and in figure 2 , the reduction in plasma virus load was 1.41 log virion RNA and DNA from simultaneous lymph node biopsies copies/mL and in lymph node virus load was 1.47 log copies/ (table 1). All baseline and early samples from both plasma and mL. In the patient shown at the right, the reduction in plasma lymph nodes showed the wild type genotype (WT) at codons virus load was 0.71 log copies/mL and in lymph node virus 48 and 90. From the 5 late samples, 2 plasma samples showed load was 0.49 log copies/mL. the mutant genotype (MU) at codon 48 and three showed WT. The simultaneous lymph node samples showed identical results, with the same 2 samples having MU and the remaining Discussion 3 having WT. Two plasma samples showed MU at codon 90 and 3 showed WT. Of lymph node samples, 1 was MU and 4
We found lymph node HIV RNA levels to be consistently higher than those found in the plasma. Although there was a were WT. In one set of simultaneous samples in which the plasma showed a MU, the corresponding lymph node sample large variation in the magnitude of this difference in individual patients, the average lymph node level was Ç1000-fold greater was WT. Altogether, of the 28 codons assayed in the 14 samples, 27 had an identical determination of WT or MU in the than the simultaneous plasma sample. This is in general agreement with the findings of other studies, in which lymph node simultaneous plasma and lymph node samples. Four late plasma samples and 3 late lymph node samples showed MU.
virus load was found to be 100-to 1000-fold higher than plasma virus load [6, 7, 10, 11] . This finding is strengthened by the One MU determination was found in plasma without a corre-/ 9d3f$$fe26
12-23-97 08:53:41 jinfa UC: J Infect fact that although a variety of technically distinct assays were both viable and possibly nonviable virus. As much nonviable viral RNA may be trapped by the lymphoid tissue, these meaused in these studies, the results were quite similar, with substantially greater HIV RNA found in the lymphoid tissue [6, surements may overestimate the actually amount of replicating virus present. This would have major implications regarding the 7, 10]. Our assay detects total RNA and therefore measures correlation between these relatively high HIV RNA levels and their actual potential to generate drug resistance mutations. In addition, the rate of mutations seen in plasma may actually reflect resistant virus generated in the lymphoid tissue. Our data suggest that drug resistance mutations develop within close temporal proximity in lymph nodes and plasma. This is in agreement with some, but not all, previous studies [11] [12] [13] . From the sparse data available to date, it appears that more potent antiretroviral regimens (including those used in our study, in which high doses of saquinavir were used to obtain greater plasma drug levels) have a substantial effect on lymph node HIV RNA levels and therefore result in similar mutations in lymph node and plasma. Less potent regimens, such as those containing only nucleoside analogue monotherapy, have little impact on lymph node HIV RNA and mutations [11] . This is supported by our findings that high-dose saquinavir reduced lymph node HIV RNA levels in the 2 patients for whom biopsies were done both before and after initiating therapy and by the substantial reductions in lymph node virus load seen with protease inhibitor-containing and combination therapy [14] [15] [16] . Whether these greater HIV RNA levels seen in lymph nodes will ultimately result in the development of drug resistance in examined on an ongoing basis [17] .
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